The COVID-19 shot from Novavax was given emergency approval by the Food and Drug Administration on Wednesday, adding a fourth vaccination to the American stockpile.
The vaccine was approved by the government for use in individuals 18 and older.
The shot will be given in an initial series of two doses spaced three weeks apart.
People who have been hesitant to receive one of the mRNA vaccines may find interest in Novavax's vaccine.
The protein-based injection was created utilizing a very distinct procedure.
However, the prospective market is minimal because 77 percent of individuals have previously had two doses of an mRNA shot.